+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Validation of a next-generation sequencing oncology panel optimized for low input DNA

Validation of a next-generation sequencing oncology panel optimized for low input DNA

Cancer Genetics 228-229: 55-63

One caveat of next-generation sequencing (NGS)-based clinical oncology testing is the high amount of input DNA required. We sought to develop a focused NGS panel that could capture hotspot regions in relevant genes requiring 0.5-10 ng input DNA. The resulting Penn Precision Panel (PPP) targeted 20 genes containing clinically significant variants relevant to many cancers. One hundred twenty-three samples were analyzed, including 83 solid tumor specimens derived from FFPE. Various input quantities of DNA (0.5-10 ng) were amplified with content-specific PCR primer pools, then sequenced on a MiSeq instrument (Illumina, Inc.) via paired-end, 2 × 186 base pair reads to an average read depth of greater than 6500x. Variants were detected using an in-house analysis pipeline. Clinical sensitivity and specificity were assessed using results from our previously validated solid tumor NGS panel; sensitivity of the PPP is 96.75% (387/400 variants) and specificity is 99.9% (8427/8428 base pairs). Variant allele frequencies (VAFs) are highly concordant across both assays (r = 0.98 p < 0.0001). The PPP is a robust, clinically validated test optimized for low-yield solid tumor specimens, capturing a high percentage of clinically relevant variants found by larger commercially available NGS panels while using only 0.5-10 ng of input DNA.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 066010193

Download citation: RISBibTeXText

PMID: 30553474

DOI: 10.1016/j.cancergen.2018.08.004

Related references

Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays. Journal of Molecular Diagnostics 19(1): 43-56, 2017

Development and validation of a targeted next generation DNA sequencing panel outperforming whole exome sequencing for the identification of clinically relevant genetic variants. Oncotarget 8(60): 102033-102045, 2017

Pre-clinical validation of a next generation sequencing testing panel. Experimental and Molecular Pathology 104(3): 170-174, 2018

Next Generation Sequencing and Multi-Gene Panel Testing: Implications for the Oncology Nurse. Seminars in Oncology Nursing 33(2): 208-218, 2017

Validation of a next-generation-sequencing cancer panel for use in the clinical laboratory. Archives of Pathology and Laboratory Medicine 139(4): 508-517, 2015

Path-26. Neuro-Oncology Next-Generation Sequencing 219-Gene Panel For Comprehensive Clinical Testing. Neuro-Oncology 20(Suppl_6): vi164, 2018

Optimized Methodology for the Generation of RNA-Sequencing Libraries from Low-Input Starting Material: Enabling Analysis of Specialized Cell Types and Clinical Samples. Methods in Molecular Biology 1706: 175-198, 2018

Validation of a next-generation sequencing assay for clinical molecular oncology. Journal of Molecular Diagnostics 16(1): 89, 2014

Validation of the Oncomine ™ focus panel for next-generation sequencing of clinical tumour samples. Virchows Archiv 473(4): 489-503, 2018

Validation and Utilization of a Clinical Next-Generation Sequencing Panel for Selected Cardiovascular Disorders. Frontiers in Cardiovascular Medicine 4: 11, 2017

Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. Oncotarget 10(24): 2384-2396, 2019

Validation of a next generation sequencing panel for detection of hotspot cancer mutations in a clinical laboratory. Pathology Research and Practice 213(2): 98, 2017

Development, analytical validation and implementation of a next generation sequencing panel to assess lysosomal diseases. Molecular Genetics and Metabolism 120(1-2): S26, 2017

A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel. Experimental and Molecular Pathology 98(3): 568-573, 2015

Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics. Virchows Archiv 472(4): 557-565, 2018